KEAP1 and non-small cell lung carcinoma: On the other hand, the mutation status of KEAP1 and NRF2 genes in NSCLC patients might have a clinical relevance and represent not only a valid predictive biomarker but also a molecular indication for the choice of a personalized therapy [164].